Skip to main content
NCBI home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1995 Jan;48(1):70–74. doi: 10.1136/jcp.48.1.70

Limited discriminant value of lipoprotein AI, lipoprotein Lp(a) and other lipoprotein particles in patients with and without early onset ischaemic heart disease.

D T Vallance 1, H A Staunton 1, A F Winder 1
PMCID: PMC502267  PMID: 7706525

Abstract

AIMS--To assess whether the ability of lipoprotein related variables to discriminate between individuals with or without premature clinical ischaemic heart disease (IHD) was improved using data on high density lipoprotein-lipoprotein AI (HDL-LpAI) fractions, alone or in combination with data on Lp(a). METHODS--Lipid and apolipoprotein concentrations were measured in 26 middle-aged men (mean age 50.3 years) with early onset IHD and coronary artery bypass grafting prior to sampling, and in 26 matched lipaemic and 26 normolipaemic asymptomatic controls. RESULTS--Triglyceride and Lp(a) concentrations were higher, while HDL cholesterol and apolipoprotein A-I (apoA-I) concentrations were lower in patients than in controls. LpAI concentrations were also lower in IHD patients and were correlated with HDL and apoA-I in both IHD and control groups. Lp(a) was not correlated with any other lipid or apolipoprotein measured in either patients or controls. Univariate discriminant function analysis showed that the proportion correctly classified as patients or controls was marginally greater using LpAI concentrations as the discriminator, which was not increased in combination with Lp(a). Serum triglycerides, HDL cholesterol, apoA-I and Lp(a) alone all had similar, but weaker, discriminant power, which increased in various combinations with LpAI. CONCLUSIONS--LpAI particle measurement may be useful in research to define mechanisms of cardiovascular protection by HDL but the discriminating power for IHD was only marginally superior to measuring total apoA-I or Lp(a) concentrations. Little further advantage arose through combining LpAI data with other variables.

Full text

PDF
70

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Atmeh R. F., Shepherd J., Packard C. J. Subpopulations of apolipoprotein A-I in human high-density lipoproteins. Their metabolic properties and response to drug therapy. Biochim Biophys Acta. 1983 Apr 13;751(2):175–188. doi: 10.1016/0005-2760(83)90172-8. [DOI] [PubMed] [Google Scholar]
  2. Aviram M., Bierman E. L., Oram J. F. High density lipoprotein stimulates sterol translocation between intracellular and plasma membrane pools in human monocyte-derived macrophages. J Lipid Res. 1989 Jan;30(1):65–76. [PubMed] [Google Scholar]
  3. Avogaro P., Bon G. B., Cazzolato G., Quinci G. B. Are apolipoproteins better discriminators than lipids for atherosclerosis? Lancet. 1979 Apr 28;1(8122):901–903. doi: 10.1016/s0140-6736(79)91375-8. [DOI] [PubMed] [Google Scholar]
  4. Barbaras R., Puchois P., Fruchart J. C., Pradines-Figueres A., Ailhaud G. Purification of an apolipoprotein A binding protein from mouse adipose cells. Biochem J. 1990 Aug 1;269(3):767–773. doi: 10.1042/bj2690767. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cheung M. C., Albers J. J. Characterization of lipoprotein particles isolated by immunoaffinity chromatography. Particles containing A-I and A-II and particles containing A-I but no A-II. J Biol Chem. 1984 Oct 10;259(19):12201–12209. [PubMed] [Google Scholar]
  6. Cheung M. C., Albers J. J. Distribution of high density lipoprotein particles with different apoprotein composition: particles with A-I and A-II and particles with A-I but no A-II. J Lipid Res. 1982 Jul;23(5):747–753. [PubMed] [Google Scholar]
  7. Coste-Burel M., Mainard F., Chivot L., Auget J. L., Madec Y. Study of lipoprotein particles LpAI and LpAI:AII in patients before coronary bypass surgery. Clin Chem. 1990 Nov;36(11):1889–1891. [PubMed] [Google Scholar]
  8. Dahlen G. H., Guyton J. R., Attar M., Farmer J. A., Kautz J. A., Gotto A. M., Jr Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation. 1986 Oct;74(4):758–765. doi: 10.1161/01.cir.74.4.758. [DOI] [PubMed] [Google Scholar]
  9. Deeb S. S., Takata K., Peng R. L., Kajiyama G., Albers J. J. A splice-junction mutation responsible for familial apolipoprotein A-II deficiency. Am J Hum Genet. 1990 Apr;46(4):822–827. [PMC free article] [PubMed] [Google Scholar]
  10. Durrington P. N., Hunt L., Ishola M., Kane J., Stephens W. P. Serum apolipoproteins AI and B and lipoproteins in middle aged men with and without previous myocardial infarction. Br Heart J. 1986 Sep;56(3):206–212. doi: 10.1136/hrt.56.3.206. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Durrington P. N., Ishola M., Hunt L., Arrol S., Bhatnagar D. Apolipoproteins (a), AI, and B and parental history in men with early onset ischaemic heart disease. Lancet. 1988 May 14;1(8594):1070–1073. doi: 10.1016/s0140-6736(88)91895-8. [DOI] [PubMed] [Google Scholar]
  12. Friedewald W. T., Levy R. I., Fredrickson D. S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972 Jun;18(6):499–502. [PubMed] [Google Scholar]
  13. Fruchart J. C., Ailhaud G. Apolipoprotein A-containing lipoprotein particles: physiological role, quantification, and clinical significance. Clin Chem. 1992 Jun;38(6):793–797. [PubMed] [Google Scholar]
  14. Fumeron F., Brigant L., Parra H. J., Bard J. M., Fruchart J. C., Apfelbaum M. Lowering of HDL2-cholesterol and lipoprotein A-I particle levels by increasing the ratio of polyunsaturated to saturated fatty acids. Am J Clin Nutr. 1991 Mar;53(3):655–659. doi: 10.1093/ajcn/53.3.655. [DOI] [PubMed] [Google Scholar]
  15. Genest J. J., Jr, Bard J. M., Fruchart J. C., Ordovas J. M., Wilson P. F., Schaefer E. J. Plasma apolipoprotein A-I, A-II, B, E and C-III containing particles in men with premature coronary artery disease. Atherosclerosis. 1991 Oct;90(2-3):149–157. doi: 10.1016/0021-9150(91)90109-g. [DOI] [PubMed] [Google Scholar]
  16. Gylling H., Vega G. L., Grundy S. M. Physiologic mechanisms for reduced apolipoprotein A-I concentrations associated with low levels of high density lipoprotein cholesterol in patients with normal plasma lipids. J Lipid Res. 1992 Oct;33(10):1527–1539. [PubMed] [Google Scholar]
  17. Hoefler G., Harnoncourt F., Paschke E., Mirtl W., Pfeiffer K. H., Kostner G. M. Lipoprotein Lp(a). A risk factor for myocardial infarction. Arteriosclerosis. 1988 Jul-Aug;8(4):398–401. doi: 10.1161/01.atv.8.4.398. [DOI] [PubMed] [Google Scholar]
  18. Koren E., Puchois P., Alaupovic P., Fesmire J., Kandoussi A., Fruchart J. C. Quantification of two different types of apolipoprotein A-I containing lipoprotein particles in plasma by enzyme-linked differential-antibody immunosorbent assay. Clin Chem. 1987 Jan;33(1):38–43. [PubMed] [Google Scholar]
  19. Maciejko J. J., Holmes D. R., Kottke B. A., Zinsmeister A. R., Dinh D. M., Mao S. J. Apolipoprotein A-I as a marker of angiographically assessed coronary-artery disease. N Engl J Med. 1983 Aug 18;309(7):385–389. doi: 10.1056/NEJM198308183090701. [DOI] [PubMed] [Google Scholar]
  20. Mbewu A. D., Bhatnagar D., Durrington P. N., Hunt L., Ishola M., Arrol S., Mackness M., Lockley P., Miller J. P. Serum lipoprotein(a) in patients heterozygous for familial hypercholesterolemia, their relatives, and unrelated control populations. Arterioscler Thromb. 1991 Jul-Aug;11(4):940–946. doi: 10.1161/01.atv.11.4.940. [DOI] [PubMed] [Google Scholar]
  21. Montali A., Vega G. L., Grundy S. M. Concentrations of apolipoprotein A-I-containing particles in patients with hypoalphalipoproteinemia. Arterioscler Thromb. 1994 Apr;14(4):511–517. doi: 10.1161/01.atv.14.4.511. [DOI] [PubMed] [Google Scholar]
  22. Nestruck A. C., Niedmann P. D., Wieland H., Seidel D. Chromatofocusing of human high density lipoproteins and isolation of lipoproteins A and A-I. Biochim Biophys Acta. 1983 Aug 29;753(1):65–73. doi: 10.1016/0005-2760(83)90099-1. [DOI] [PubMed] [Google Scholar]
  23. Parra H. J., Mezdour H., Ghalim N., Bard J. M., Fruchart J. C. Differential electroimmunoassay of human LpA-I lipoprotein particles on ready-to-use plates. Clin Chem. 1990 Aug;36(8 Pt 1):1431–1435. [PubMed] [Google Scholar]
  24. Puchois P., Ghalim N., Zylberberg G., Fievet P., Demarquilly C., Fruchart J. C. Effect of alcohol intake on human apolipoprotein A-I-containing lipoprotein subfractions. Arch Intern Med. 1990 Aug;150(8):1638–1641. [PubMed] [Google Scholar]
  25. Puchois P., Kandoussi A., Fievet P., Fourrier J. L., Bertrand M., Koren E., Fruchart J. C. Apolipoprotein A-I containing lipoproteins in coronary artery disease. Atherosclerosis. 1987 Nov;68(1-2):35–40. doi: 10.1016/0021-9150(87)90091-8. [DOI] [PubMed] [Google Scholar]
  26. Rubin E. M., Krauss R. M., Spangler E. A., Verstuyft J. G., Clift S. M. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature. 1991 Sep 19;353(6341):265–267. doi: 10.1038/353265a0. [DOI] [PubMed] [Google Scholar]
  27. Seed M., Hoppichler F., Reaveley D., McCarthy S., Thompson G. R., Boerwinkle E., Utermann G. Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia. N Engl J Med. 1990 May 24;322(21):1494–1499. doi: 10.1056/NEJM199005243222104. [DOI] [PubMed] [Google Scholar]
  28. Sniderman A., Shapiro S., Marpole D., Skinner B., Teng B., Kwiterovich P. O., Jr Association of coronary atherosclerosis with hyperapobetalipoproteinemia [increased protein but normal cholesterol levels in human plasma low density (beta) lipoproteins]. Proc Natl Acad Sci U S A. 1980 Jan;77(1):604–608. doi: 10.1073/pnas.77.1.604. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Staunton A., Vallance D. T., Child A., Camm A. J., Winder A. F. Unrecognized dyslipoproteinemia in United Kingdom families recruited to a genetic register because of unexplained coronary heart disease. J Lab Clin Med. 1994 Jun;123(6):842–848. [PubMed] [Google Scholar]
  30. Stensel D. J., Hardman A. E., Brooke-Wavell K., Vallance D., Jones P. R., Norgan N. G., Winder A. F. Brisk walking and serum lipoprotein variables in formerly sedentary men aged 42-59 years. Clin Sci (Lond) 1993 Dec;85(6):701–708. doi: 10.1042/cs0850701. [DOI] [PubMed] [Google Scholar]
  31. Välimäki M., Laitinen K., Ylikahri R., Ehnholm C., Jauhiainen M., Bard J. M., Fruchart J. C., Taskinen M. R. The effect of moderate alcohol intake on serum apolipoprotein A-I-containing lipoproteins and lipoprotein (a). Metabolism. 1991 Nov;40(11):1168–1172. doi: 10.1016/0026-0495(91)90211-e. [DOI] [PubMed] [Google Scholar]
  32. Warnick G. R., Albers J. J. A comprehensive evaluation of the heparin-manganese precipitation procedure for estimating high density lipoprotein cholesterol. J Lipid Res. 1978 Jan;19(1):65–76. [PubMed] [Google Scholar]
  33. Wiklund O., Angelin B., Olofsson S. O., Eriksson M., Fager G., Berglund L., Bondjers G. Apolipoprotein(a) and ischaemic heart disease in familial hypercholesterolaemia. Lancet. 1990 Jun 9;335(8702):1360–1363. doi: 10.1016/0140-6736(90)91242-3. [DOI] [PubMed] [Google Scholar]
  34. Wilson P. W., Garrison R. J., Castelli W. P., Feinleib M., McNamara P. M., Kannel W. B. Prevalence of coronary heart disease in the Framingham Offspring Study: role of lipoprotein cholesterols. Am J Cardiol. 1980 Oct;46(4):649–654. doi: 10.1016/0002-9149(80)90516-0. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES